1 |
Brewer, H.B. Jr. (2004). Increasing HDL cholesterol levels. N. Engl. J. Med. 350, 1491-1494.
DOI
ScienceOn
|
2 |
Barter, P.J., Brewer, H.B. Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., and Tall, A.R. (2003). Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 160-167.
DOI
ScienceOn
|
3 |
Bell, T.A., Graham, M.J., Lee, R.G., Mullick, A.E., Fu, W., Norris, D., and Crooke, R.M. (2013). Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice. J. Lipid Res. 54, 2647-2657.
DOI
ScienceOn
|
4 |
de Grooth, G.J., Smilde, T.J., Van Wissen, S., Klerkx, A.H., Zwinderman, A.H., Fruchart, J.C., Kastelein, J.J., Stalenhoef, A.F., and Kuivenhoven, J.A. (2004). The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 173, 261-267.
DOI
ScienceOn
|
5 |
Brousseau, M.E., Schaefer, E.J., Wolfe, M.L., Bloedon, L.T., Digenio, A.G., Clark, R.W., Mancuso, J.P., and Rader, D.J. (2004). Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505-1515.
DOI
ScienceOn
|
6 |
Brown, M.L., Inazu, A., Hesler, C.B., Agellon, L.B., Mann, C., Whitlock, M.E., Marcel, Y.L., Milne, R.W., Koizumi, J., Mabuchi, H., et al. (1989). Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342, 448-451.
DOI
ScienceOn
|
7 |
Curb, J.D., Abbott, R.D., Rodriguez, B.L., Masaki, K., Chen, R., Sharp, D.S., and Tall, A.R. (2004). A prospective study of HDLC and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45, 948-953.
DOI
ScienceOn
|
8 |
Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W., Gotto, A.M. Jr., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622.
DOI
ScienceOn
|
9 |
Glueck, C.J., Gartside, P., Fallat, R.W., Sielski, J., and Steiner, P.M. (1976). Longevity syndromes: familial hypo- and familial hyper--lipoproteinemia. J. Lab. Clin. Med. 88, 941-957.
|
10 |
Gaynor, B.J., Sand, T., Clark, R.W., Aiello, R.J., Bamberger, M.J., and Moberly, J.B. (1994). Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis 110, 101-109.
DOI
|
11 |
Haraki, T., Inazu, A., Yagi, K., Kajinami, K., Koizumi, J., and Mabuchi, H. (1997). Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis 132, 229-236.
DOI
ScienceOn
|
12 |
Gordon, T., Kannel, W.B., Castelli, W.P., and Dawber, T.R. (1981). Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch. Intern. Med. 141, 1128-1131.
DOI
ScienceOn
|
13 |
Ha, Y.C., and Barter, P.J. (1982). Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp. Biochem. Physiol. B. 71, 265-269.
DOI
ScienceOn
|
14 |
Han K.H., Park, Y.B., Chae, I.H., Kim, H.S., Sohn, D.W., Oh, B.H., Lee, M.M, Choi, Y.S., Seo, J.D., Lee, Y.W., et al. (1996). CETP (cholesteryl esters transfer protein) deficiency caused by genetic mutation in the CETP gene in normal Korean population. Korean Circ. J. 26, 500-506.
DOI
|
15 |
Hirano, K., Yamashita, S., Kuga, Y., Sakai, N., Nozaki, S., Kihara, S., Arai, T., Yanagi, K., Takami, S., Menju, M., et al. (1995). Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15, 1849-1856.
DOI
|
16 |
Inazu, A.1., Brown, M.L., Hesler, C.B., Agellon, L.B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., and Tall, A.R. (1990). Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238.
DOI
ScienceOn
|
17 |
Huang, Z., Inazu, A., Nohara, A., Higashikata, T., and Mabuchi, H. (2002). Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (Lond). 103, 587-594.
DOI
|
18 |
Kastelein, J.J., van Leuven, S.I., Burgess, L., Evans, G.W., Kuivenhoven, J.A., Barter, P.J., Revkin, J.H., Grobbee, D.E., Riley, W.A., Shear, C.L., et al. (2007). Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620-1630.
DOI
ScienceOn
|
19 |
Inazu, A.1., and Mabuchi, H. (2003). Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia. Curr. Opin. Investig. Drugs 4, 291-297.
|
20 |
Inazu, A.1., Jiang, X.C., Haraki, T., Yagi, K., Kamon, N., Koizumi, J., Mabuchi, H., Takeda, R., Takata, K., Moriyama, Y., et al. (1994). Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high-density lipoprotein cholesterol. J. Clin. Invest. 94, 1872-1882.
DOI
ScienceOn
|
21 |
Koizumi, J., Mabuchi, H., Yoshimura, A., Michishita, I., Takeda, M., Itoh, H., Sakai, Y., Sakai, T., Ueda, K., and Takeda, R. (1985). Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 58, 175-186.
DOI
ScienceOn
|
22 |
Linsel-Nitschke P.I., and Tall A.R. (2005). HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4, 193-205.
DOI
ScienceOn
|
23 |
Miwa, K., Inazu, A., Kawashiri, M., Nohara, A., Higashikata, T., Kobayashi, J., Koizumi, J., Nakajima, K., Nakano, T., Niimi, M., et al. (2009). Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin. Chim. Acta 402, 19-24.
DOI
ScienceOn
|
24 |
Marotti, K.R., Castle, C.K., Boyle, T.P., Lin, A.H., Murray, R.W., and Melchior, G.W. (1993). Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364, 73-75.
DOI
ScienceOn
|
25 |
National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). (2002). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106, 3143-3421.
|
26 |
Matsuura, F., Wang, N., Chen, W., Jiang, X.C., and Tall, A.R. (2006). HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J. Clin. Invest. 116, 1435-1442.
DOI
ScienceOn
|
27 |
Moriyama, Y., Okamura, T., Inazu, A., Doi, M., Iso, H., Mouri, Y., Ishikawa, Y., Suzuki, H., Iida, M., Koizumi, J., et al. (1998). A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27, 659-667.
DOI
ScienceOn
|
28 |
Nissen, SE., Tardif, J.C., Nicholls, S.J., Revkin, J.H., Shear, C.L., Duggan, W.T., Ruzyllo, W., Bachinsky, W.B., Lasala, G.P., Tuzcu, E.M., et al. (2007). Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316.
DOI
ScienceOn
|
29 |
Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W., Arnold, J.M., Wun, C.C., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in participants with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009.
DOI
ScienceOn
|
30 |
Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., and Shinkai, H. (2000). A cholesteryl ester transfer protein in hibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207.
DOI
ScienceOn
|
31 |
Olsson, A.G., Schwartz, G.G., Szarek, M., Sasiela, W.J., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., and Zeiher, A. (2005). High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACLE trial. Eur. Heart J. 26, 890-896.
DOI
ScienceOn
|
32 |
Pedersen, T.R., Kjekshus, J., Berg, K., Haghfelt, T., Faergeman, O., Faergeman, G., Pyörälä, K., Miettinen, T., Wilhelmsen, L., Olsson, A.G., et al. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389.
|
33 |
Rittershaus, C.W., Miller, D.P., Thomas, L.J., Picard, M.D., Honan, C.M., Emmett, C.D., Pettey, C.L., Adari, H., Hammond, R.A., Beattie, D.T., et al. (2000). Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 2106-2112.
DOI
ScienceOn
|
34 |
Schaefer, E.J. (2013). Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Curr. Opin. Lipidol. 24, 259-264.
DOI
|
35 |
Tall, A.R. (1993). Plasma cholesteryl ester transfer protein. J. Lipid Res. 34, 1255-1274.
|
36 |
Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H., and Packard, C.J. (1995). For the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301-1307.
DOI
ScienceOn
|
37 |
Sikorski, J.A. (2006). Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. J. Med. Chem. 49, 1-22.
DOI
ScienceOn
|
38 |
Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., Kamada, M., and Mizushima, A. (1998). Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273, 5033-5036.
DOI
ScienceOn
|
39 |
Wolfe, M.L., and Rader, D.J. (2004). Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications. Circulation 110, 1338-1340.
DOI
ScienceOn
|
40 |
Zhong, S., Sharp, D.S., Grove, J.S., Bruce, C., Yano, K., Curb, J.D., and Tall, A.R. (1996). Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917-2923.
DOI
ScienceOn
|
41 |
Hirano, K., Yamashita, S., Nakajima, N., Arai, T., Maruyama, T., Yoshida, Y., Ishigami, M., Sakai, N., Kameda-Takemura, K., and Matsuzawa, Y. (1997). Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17, 1053-1059.
DOI
ScienceOn
|
42 |
Agellon, L.B., Walsh, A., Hayek, T., Moulin, P., Jiang, X.C., Shelanski, S.A., Breslow, J.L., and Tall, A.R. (1991). Reduced high-density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266, 10796-10801.
|